# ELI-002 7P

Source: https://onco.cc/drugs/eli-002-7p/  
OnCo record `eli-002-7p` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.

## Summary

Elicio's amphiphile peptides (7 mKRAS antigens) plus CpG adjuvant, engineered to drain to lymph nodes. Phase 1 AMPLIFY-201 induced mKRAS-specific T cells in most patients with ctDNA reductions. Randomised phase 2 AMPLIFY-7P (adjuvant PDAC, results June 2026) did not meet its primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses reported ~14% absolute DFS benefit during active treatment. Elicio is refining a phase 3 strategy around R0-resected patients.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-06
- Modality: Off-the-shelf lymph-node-targeted KRAS peptide vaccine
- Mechanism: Albumin-binding lipid tails carry mutant-KRAS peptides to lymph nodes for dendritic cell presentation.

## Sources

- Elicio AMPLIFY-7P results (June 2026): https://elicio.com/press_releases/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-outlines-refined-phase-3-development-strategy-for-eli-002-7p-in-adjuvant-pancreatic-cancer/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Elicio Therapeutics](https://onco.cc/companies/elicio-therapeutics/)
- trials: [AMPLIFY-7P](https://onco.cc/trials/amplify-7p/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)
- terms: [Pancreatic cancer: the failed and stopped programmes and why](https://onco.cc/terms/pancreatic-failed-programmes/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)

---
JSON: https://onco.cc/api/v1/entities/eli-002-7p.json